{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:00:03Z","timestamp":1780678803657,"version":"3.54.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,17]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Preventing the progression of coronavirus disease 2019 (COVID-19) is a critical issue, particularly in patients with comorbidities such as asthma. However, real-world data on the effectiveness of oral antivirals in patients with asthma and non-severe COVID-19 are limited. This study was conducted to evaluate the effectiveness of 2 oral antivirals, nirmatrelvir\/ritonavir (NMV-r) and molnupiravir, in reducing adverse outcomes in asthmatic patients with non-severe COVID-19. This retrospective cohort study included non-hospitalized adults with asthma who were diagnosed with COVID-19 between January 1, 2022, and March 16, 2024, using data from the TriNetX Research Network. The study group received NMV-r or molnupiravir; the control group received no antivirals. Covariates were balanced between the groups using propensity score matching. The primary outcome was the composite incidence of all-cause mortality, all-cause hospitalization, and mechanical ventilation use within 30 days. After matching, each group comprised 19,235 patients. The study group showed significantly lower composite primary outcome (hazard ratio [HR]: 0.57; 95% confidence interval [CI]: 0.49\u20130.66). Specifically, the study group was associated with significantly lower risk of all-cause hospitalization (HR: 0.59; 95% CI: 0.50\u20130.69) and all-cause mortality (HR: 0.34; 95% CI: 0.16\u20130.73) and mechanical ventilation requirements (HR: 0.08; 95% CI: 0.01\u20130.58). Significantly risk reduction was also observed in subgroups including both sexes, different ages, those with hypertension, dyslipidemia, diabetes mellitus, those receiving NMV-r, and those who had received less than 1 dose and more than 3 doses of vaccine. Our findings suggest oral antivirals, particularly NMV-r, reduce adverse outcomes in asthmatic patients with non-severe COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048378","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:02:23Z","timestamp":1776434543000},"page":"e48378","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of oral antivirals in reducing adverse outcomes in asthmatic patients with non-severe COVID-19: A multi-institutional retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Shao-Chi","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Radiology, Kaohsiung Medical University Chung-Ho Memorial Hospital Center, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Tsai","sequence":"additional","affiliation":[{"name":"Center for Integrative Medicine, Chi Mei Medical Center, Tainan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ming","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan City, Taiwan"},{"name":"Department of Dental Laboratory Technology, Min-Hwei College of Health Care Management, Tainan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Hospital, Tainan City, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1208\/s12248-020-00532-2","article-title":"Recent developments on therapeutic and diagnostic approaches for COVID-19.","volume":"23","author":"Majumder","year":"2021","journal-title":"AAPS J"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jmii.2020.02.012","article-title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths.","volume":"53","author":"Lai","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"e2323349","DOI":"10.1001\/jamanetworkopen.2023.23349","article-title":"Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis of 4 randomized clinical trials.","volume":"6","author":"Theodore","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals guidelines-recommendations for severe asthma.","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"Suppl 1","key":"R7-20260605","first-page":"S2","article-title":"Asthma: definitions and pathophysiology.","volume":"5","author":"Mims","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","article-title":"Asthma epidemiology and risk factors.","volume":"42","author":"Stern","year":"2020","journal-title":"Semin Immunopathol"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/02770903.2021.1881970","article-title":"Asthma and COVID-19; different entities, same outcome: a meta-analysis of 107,983 patients.","volume":"59","author":"Hussein","year":"2022","journal-title":"J Asthma"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1164\/rccm.202008-3266OC","article-title":"Asthma in adult patients with COVID-19. Prevalence and risk of severe disease.","volume":"203","author":"Terry","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/vaccines11010089","article-title":"Comorbid asthma increased the risk for COVID-19 mortality in Asia: a meta-analysis.","volume":"11","author":"Shi","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/crj.13480","article-title":"Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVID-19).","volume":"16","author":"Kwok","year":"2022","journal-title":"Clin Respir J"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1093\/cid\/ciac724","article-title":"Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19.","volume":"78","author":"Bhimraj","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/v14081706","article-title":"The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.","volume":"14","author":"Lai","year":"2022","journal-title":"Viruses"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19.","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research.","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching.","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance.","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/v15030610","article-title":"Real-world study on effectiveness of molnupiravir and nirmatrelvir-ritonavir in unvaccinated patients with chronic respiratory diseases with confirmed SARS-CoV-2 infection managed in out-patient setting.","volume":"15","author":"Kwok","year":"2023","journal-title":"Viruses"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"e28889","DOI":"10.1002\/jmv.28889","article-title":"Comparative efficacy and safety of nirmatrelvir\/ritonavir and molnupiravir for COVID-19: a systematic review and meta-analysis.","volume":"95","author":"Amani","year":"2023","journal-title":"J Med Virol"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/COPD.S440895","article-title":"Real-world effectiveness study of nirmatrelvir-ritonavir or molnupiravir in hospitalized unvaccinated patients with chronic respiratory diseases and moderate COVID-19 at presentation.","volume":"19","author":"Kwok","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:01:35Z","timestamp":1780675295000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048378","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2025-11-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}